PubMed pubmed.ncbi.nlm.nih.gov [31] Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist, a step forward in the treatment of diabetes and obesity
In addition, the analysis of the EXSCEL trial revealed that a composite end-point of new macroalbuminuria, 40% eGFR decline or renal death was reduced by the addition of exenatide in T2DM [26]
But in some cases, people shed more than just pounds
Discover how this life-changing surgery can improve your health and overall well-being
This is not a character failure
Gastrointestinal issues such as nausea and vomiting are the most commonly experienced side effects with GLP-1 drugs, which was seen in studies of the pills as well